Investigating TIL Therapy & PBL Therapy for Cancer - Iovance Biotherapeutics
Learn about our investigational tumor infiltrating lymphocyte (TIL) therapy and peripheral blood lymphocyte (PBL) therapy. View our clinical trials and pipeline.
Total Visits
Avg. Visit Duration
Pages per Visit
Bounce Rate
Registration Date
| Month | Traffic |
|---|---|
| 2025-02 | 28.165 |
| 2025-03 | 26.475 |
| 2025-04 | 26.235 |
| 2025-05 | 29.118 |
| Source | Traffic Share |
|---|---|
| search | 51.20% |
| direct | 40.72% |
| referrals | 6.24% |
| social | 1.00% |
| paid referrals | 0.77% |
| 0.08% |
| Region | Percentage |
|---|---|
| United States | 68.23% |
| United Kingdom | 7.76% |
| Germany | 6.65% |
| Canada | 5.41% |
| NL | 4.76% |
| Keyword | Traffic | Volume | CPC |
|---|---|---|---|
| iovance | 623 | 6,230 | $1.73 |
| iovance biotherapeutics | 786 | 7,860 | $1.13 |
| iovance biotherapeutics director canidates | 0 | 0 | $0.00 |
| iova investor relations | 77 | 770 | $0.00 |
| fda approves amtagvi | 27 | 270 | $0.00 |